CRSwNP causes swelling in the sinuses and leads to growths called polyps in the nose.
These can block airflow, reduce your sense of smell, and make you feel congested.
It’s estimated that up to 320 million people around the world live with this condition. Tezspire works by blocking a protein called thymic stromal lymphopoietin (TSLP), which plays a key role in causing inflammation in the airways and sinuses. This inflammation can make breathing difficult and worsen symptoms of CRSwNP and asthma. First approved in 2021 as an add-on treatment for severe asthma, Tezspire offers a new option for people living with this chronic condition.
Why Was It Approved?
Tezspire was approved to treat CRSwNP after studies showed it helped shrink nasal polyps and ease nasal congestion. In the study, people received either Tezspire or a placebo every four weeks for a year, along with their usual nasal steroid treatment. Those who got this medicine had more improvement in both polyp size and congestion than those who got the placebo. Benefits appeared as early as week 2 for congestion and week 4 for polyp size and were maintained for a year. Tezspire also reduced the need for nasal polyp surgery by 98% and cut steroid use by 88%. The safety of this medicine in people with CRSwNP was similar to what was seen in people with asthma. Common side effects in CRSwNP are cold or flu-like symptoms (such as sore throat, stuffy nose, or cough), nosebleeds, back pain, joint pain, and reactions at the injection site, such as redness or swelling.
What Do I Need to Know?
Tezspire is given as a shot under the skin once every four weeks. It comes in a single-dose vial, a prefilled syringe, or a prefilled pen. Your health care provider may give you the injection, or they may train you or a caregiver to give it at home using the prefilled pen.
